옵션 체인은 다양한 행사가격과 만기일에 대한 Travere Therapeutics의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Travere Therapeutics에 대한 시장 심리를 평가합니다..

Travere Therapeutics (NASDAQ:TVTX) 주식, 옵션 체인

Travere Therapeutics

Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) - rare kidney disorders that often cause end-stage kidney disease.

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

COST

MITQ

NVNO

SCHL

TVTX

금요일 오전 (현지 시간 기준) 미국 주식 선물 거래가 혼조세를 보이고 있는 가운데 오늘 투자자들의 관심을 끌 수 있는 주식은 다음과 같다: 1. 코스트코 홀세일(NASDAQ:COST)는 4분기 긍정적인 실적을 발표했지만, 매출은 예상에 미치지 못했다. 이 회사는 분기 매출이 796.97억 달러로, 컨센서스 추정치인 799.73억 달러를 밑돌았다고 보고했다. 이 회원제 소매업체는 분기당 주당 순이익이 5.29달러로, 애널리스트 추정치인 5.08달러를 초과했다고 보고했다. 코스트코의 주식은 시간외 거래에서 1.4% 하락한 888.62달러에 거래되었다.

금요일 주목해야 할 주식: 코스트코, 스콜라스틱, 무빙 이미지 그리고 2종목

Travere Therapeutics, Inc. - Common Stock

Travere Therapeutics Inc

<p><strong>IonQ Inc.</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IONQ#NYSE">IONQ</a>) shares are trading lower Monday, pulling back after rallying in recent weeks. Here&#8217;s what <a href="https://www.benzinga.com/quote/IONQ/news">you need to know.</a></p>
<p><strong>What To Know:</strong> IonQ shares are up more than 60% since the start of the month, and have more than doubled since the start of the year. The stock opened lower Monday and quickly traded down from around $28.50 to around $22.30 before bouncing and leveling off between $24 and $25 per share.</p>
<p>IonQ shares really took off after the company reported quarterly financials near the start of November. IonQ reported <a href="https://www.benzinga.com/news/earnings/24/11/41817317/ionq-stock-is-soaring-thursday-whats-going-on">third-quarter revenue</a> of $12.4 million, beating analyst expectations of $10.56 million. The company posted a loss of 24 cents per share, versus an expected loss of 21 cents per share, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>. </p>
<p>The company&#8217;s quarterly report was accompanied by a series of partnerships and contract announcements, including a $54.5 million contract with the U.S. Air Force Research Lab and the creation of a new quantum application development center in collaboration with AstraZeneca.</p>
<p>Following the report, several analysts raised <a href="https://www.benzinga.com/analyst-stock-ratings">price targets</a> on IonQ, which helped shares sustain positive momentum throughout the week. The company also announced that it was <a href="https://www.benzinga.com/trading-ideas/movers/24/11/41945075/ionq-stock-is-trading-higher-today-whats-going-on">issued five new U.S. patents</a>, covering advancements in quantum computing across multiple industries and applications.</p>
<p>IonQ shares briefly saw some buyers come into the name in afternoon trading on Monday after the company demonstrated a hybrid quantum computing workflow using the <strong>NVIDIA Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) CUDA-Q platform and its quantum hardware.</p>
<p>IonQ and Nvidia presented the application workflow together at SC24. The companies believe the new approaches have potential relevance in many chemistry-focused commercial applications.</p>
<p>&#8220;IonQ is building on its approach of accelerating AI, scientific compute, and other supercomputing workloads with quantum hardware – enabling entirely new ways to approach previously unsolvable problems,&#8221; said <strong>Dean Kassmann</strong>, SVP of Engineering &amp; Technology at IonQ. </p>
<p>&#8220;Today&#8217;s molecular modeling demonstration illustrates why CUDA-Q is a great platform for achieving seamless integration and top-tier performance with our leading quantum hardware.&#8221;</p>
<p><strong>IonQ Price Action: </strong>IonQ shares were down 15.4% at $24.66 at the time of writing, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro.</a></p>
<p><figure class="wp-block-image size-large is-resized"><a href="https://benzinga.slack.com/archives/D072651PB4K/p1727794380964569"><img loading="lazy" decoding="async" width="1024" height="543" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/18145521/ionq-1-1024x543.png" alt="" class="wp-image-653689" style="width:450px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/18145521/ionq-1-1024x543.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/18145521/ionq-1-300x159.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/18145521/ionq-1-768x407.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/18145521/ionq-1.png 1165w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure></p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/news/fda/24/11/42046777/ispire-and-ike-tech-advance-fda-backed-age-verification-tech-to-curb-youth-vaping">Ispire And IKE Tech Advance FDA-Backed Age Verification Tech To Curb Youth Vaping</a></strong></li>
</ul>
<p><em>Image Via Shutterstock.</em></p>


Movers

IONQ

NVDA

What's Going On With IonQ Stock Today?

<p><i>- NKTR-422 demonstrated inflammation resolution and tissue repair in multiple preclinical models of chronic inflammatory conditions -</i></p>
<p>SAN FRANCISCO, Nov. 18, 2024 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) today announced its oral presentation highlighting preclinical data on NKTR-422 at the 2024 American College of Rheumatology (ACR)&nbsp;conference, being held in Washington, D.C. from November 14-19, 2024.</p>
<p>NKTR-422 is a novel modified&nbsp;hematopoietic colony stimulating factor (CSF) protein engineered to selectively modulate resolution processes of inflammation by targeting the expansion, reprograming and activation of anti-inflammatory tissue resident macrophages.</p>
<p>Currently approved inflammatory disease therapies are not designed to achieve inflammation resolution or tissue repair, which are both required for remission.1 Nektar has identified a CSF-1R agonist with a differentiated pharmacokinetic (PK)/pharmacodynamic (PD) profile compared to the native CSF-1 cytokine. Reduced clearance enables sustained PD activity from a single dose, unlike historical multiple dose per day necessary regimens of recombinant human CSF-1 administration. This CSF-1R agonist, NKTR-422, demonstrated inflammation resolution and tissue repair markers induction in tissue resident macrophages without induction of monocytosis and enhanced the efficacy of inflammatory cytokine blockade in rodent models.</p>


Biotech

General

NKTR

Nektar Therapeutics Presents First Preclinical Data From Novel CSF-1 Program, NKTR-422, At 2024 American College Of Rheumatology  Convergence; NKTR-422 Demonstrated Inflammation Resolution And Tissue Repair In Multiple Preclinical Models Of Chronic Inflammatory Conditions

<p>Financial giants have made a conspicuous bearish move on Insmed. Our analysis of options history for Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) revealed 13 unusual trades.</p>
<p>Delving into the details, we found 7% of traders were bullish, while 76% showed bearish tendencies. Out of all the trades we spotted, 10 were puts, with a value of $855,036, and 3 were calls, valued at $419,310.</p>
<h3>Expected Price Movements</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $62.5 to $85.0 for Insmed over the recent three months. </p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>In today's trading context, the average open interest for options of Insmed stands at 2968.25, with a total volume reaching 15,604.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Insmed, situated within the strike price corridor from $62.5 to $85.0, throughout the last 30 days.</p>
<h3>Insmed Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731961828_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>INSM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$1.2</td>
<td>$0.75</td>
<td>$1.2</td>
<td>$85.00</td>
<td>$360.0K</td>
<td>7.1K</td>
<td>3.0K</td>
</tr>
<tr>
<td>INSM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$4.1</td>
<td>$3.8</td>
<td>$4.06</td>
<td>$62.50</td>
<td>$150.3K</td>
<td>504</td>
<td>2.3K</td>
</tr>
<tr>
<td>INSM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$4.5</td>
<td>$3.4</td>
<td>$3.9</td>
<td>$62.50</td>
<td>$142.3K</td>
<td>504</td>
<td>365</td>
</tr>
<tr>
<td>INSM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$4.0</td>
<td>$3.7</td>
<td>$4.0</td>
<td>$62.50</td>
<td>$138.4K</td>
<td>504</td>
<td>1.5K</td>
</tr>
<tr>
<td>INSM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$4.0</td>
<td>$3.7</td>
<td>$4.0</td>
<td>$62.50</td>
<td>$123.2K</td>
<td>504</td>
<td>746</td>
</tr>
</tbody>
</table>
</p>
<h3>About Insmed</h3>
<p>Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.</p>
<p>After a thorough review of the options trading surrounding Insmed, we move to examine the company in more detail. This includes an assessment of its current market status and performance.</p>
<h3>Where Is Insmed Standing Right Now?</h3>
<ul>
<li>With a trading volume of 891,951, the price of INSM is down by -0.03%, reaching $66.27.</li>
<li>Current RSI values indicate that the stock is may be approaching oversold.</li>
<li>Next earnings report is scheduled for 94 days from now.</li>
</ul>
<h3>Professional Analyst Ratings for Insmed</h3>
<p>2 market experts have recently issued ratings for this stock, with a consensus target price of $97.5.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; In a cautious move, an analyst from Truist Securities downgraded its rating to Buy, setting a price target of $105.<br />
&#x2A; Reflecting concerns, an analyst from HC Wainwright &amp; Co. lowers its rating to Buy with a new price target of $90.</p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Insmed options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


Options

INSM

Insmed's Options: A Look at What the Big Money is Thinking

Bakkt Holdings, Inc. Class A Common Stock

BKKT

Bakkt Holdings Shares Resume Trade Then Again Halted On Circuit Breaker To The Upside, Stock Now Up 65.2%

<p>Financial giants have made a conspicuous bearish move on Trump Media &amp; Technology. Our analysis of options history for Trump Media &amp; Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>) revealed 58 unusual trades.</p>
<p>Delving into the details, we found 39% of traders were bullish, while 44% showed bearish tendencies. Out of all the trades we spotted, 22 were puts, with a value of $1,154,360, and 36 were calls, valued at $3,115,636.</p>
<h3>Projected Price Targets</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $24.0 to $115.0 for Trump Media &amp; Technology over the recent three months. </p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Trump Media &amp; Technology's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Trump Media &amp; Technology's substantial trades, within a strike price spectrum from $24.0 to $115.0 over the preceding 30 days.</p>
<h3>Trump Media &amp; Technology Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731961823_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>DJT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$12.5</td>
<td>$11.65</td>
<td>$12.5</td>
<td>$25.00</td>
<td>$249.8K</td>
<td>416</td>
<td align="right">200</td>
</tr>
<tr>
<td>DJT</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$13.1</td>
<td>$11.55</td>
<td>$12.35</td>
<td>$25.00</td>
<td>$247.0K</td>
<td>416</td>
<td align="right">400</td>
</tr>
<tr>
<td>DJT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$12.45</td>
<td>$12.1</td>
<td>$12.1</td>
<td>$25.00</td>
<td>$242.0K</td>
<td>416</td>
<td align="right">600</td>
</tr>
<tr>
<td>DJT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/19/25</td>
<td>$10.85</td>
<td>$10.4</td>
<td>$10.4</td>
<td>$25.00</td>
<td>$156.0K</td>
<td>455</td>
<td align="right">300</td>
</tr>
<tr>
<td>DJT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$7.35</td>
<td>$7.05</td>
<td>$7.05</td>
<td>$50.00</td>
<td>$141.0K</td>
<td>1.2K</td>
<td align="right">835</td>
</tr>
</tbody>
</table>
</p>
<h3>About Trump Media &amp; Technology</h3>
<p>Trump Media &amp; Technology Group Corp is a media and technology company rooted in social media, digital streaming, information technology infrastructure, and more. Its initial product launch will focus on its social media platform, Truth Social, which encourages an open, free, and honest global conversation without discriminating against political ideology.</p>
<p>In light of the recent options history for Trump Media &amp; Technology, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Present Market Standing of Trump Media &amp; Technology</h3>
<ul>
<li>With a volume of 12,214,290, the price of DJT is down -2.48% at $27.4. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 77 days.</li>
</ul>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.</p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Trump Media &amp; Technology with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


Decoding Trump Media & Technology's Options Activity: What's the Big Picture?

<p>Whales with a lot of money to spend have taken a noticeably bearish stance on <strong>Vertex Pharmaceuticals</strong>.</p>
<p>Looking at options history for Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) we detected 8 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 37% of the investors opened trades with bullish expectations and 50% with bearish.</p>
<p>From the overall spotted trades, 5 are puts, for a total amount of $266,785 and 3, calls, for a total amount of $162,840.</p>
<h3>Projected Price Targets</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $420.0 to $550.0 for Vertex Pharmaceuticals during the past quarter. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Vertex Pharmaceuticals's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Vertex Pharmaceuticals's whale trades within a strike price range from $420.0 to $550.0 in the last 30 days. </p>
<h3>Vertex Pharmaceuticals Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731961818_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th align="right"><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>VRTX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$15.8</td>
<td>$14.6</td>
<td>$15.0</td>
<td>$450.00</td>
<td>$99.0K</td>
<td align="right">500</td>
<td align="right">66</td>
</tr>
<tr>
<td>VRTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$46.8</td>
<td>$41.8</td>
<td>$44.0</td>
<td>$440.00</td>
<td>$88.0K</td>
<td align="right">439</td>
<td align="right">20</td>
</tr>
<tr>
<td>VRTX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$15.3</td>
<td>$13.6</td>
<td>$15.0</td>
<td>$450.00</td>
<td>$51.0K</td>
<td align="right">500</td>
<td align="right">100</td>
</tr>
<tr>
<td>VRTX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$50.9</td>
<td>$44.8</td>
<td>$46.02</td>
<td>$420.00</td>
<td>$46.0K</td>
<td align="right">0</td>
<td align="right">10</td>
</tr>
<tr>
<td>VRTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$2.95</td>
<td>$2.65</td>
<td>$2.65</td>
<td>$550.00</td>
<td>$40.2K</td>
<td align="right">69</td>
<td align="right">152</td>
</tr>
</tbody>
</table>
</p>
<h3>About Vertex Pharmaceuticals</h3>
<p>Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.</p>
<p>Following our analysis of the options activities associated with Vertex Pharmaceuticals, we pivot to a closer look at the company's own performance.</p>
<h3>Vertex Pharmaceuticals's Current Market Status</h3>
<ul>
<li>With a volume of 565,702, the price of VRTX is up 0.06% at $466.0. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 77 days.</li>
</ul>
<h3>Expert Opinions on Vertex Pharmaceuticals</h3>
<p>In the last month, 5 experts released ratings on this stock with an average target price of $492.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Maintaining their stance, an analyst from Scotiabank continues to hold a Sector Perform rating for Vertex Pharmaceuticals, targeting a price of $486.<br />
&#x2A; Consistent in their evaluation, an analyst from JP Morgan keeps a Overweight rating on Vertex Pharmaceuticals with a target price of $503.<br />
&#x2A; Maintaining their stance, an analyst from Oppenheimer continues to hold a Outperform rating for Vertex Pharmaceuticals, targeting a price of $540.<br />
&#x2A; An analyst from Cantor Fitzgerald downgraded its action to Overweight with a price target of $480.<br />
&#x2A; Consistent in their evaluation, an analyst from RBC Capital keeps a Sector Perform rating on Vertex Pharmaceuticals with a target price of $451. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Vertex Pharmaceuticals, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


VRTX

A Closer Look at Vertex Pharmaceuticals's Options Market Dynamics

WIIM

FANG

SHEL

Shares of energy and oil stocks are trading higher amid a rise in the price of oil, which gained on Russia-Ukraine tensions and a Norway oilfield shutdown.

Bakkt Holdings shares are trading higher following a report suggesting Trump Media and Technology Group is in talks to buy the company.

<p><a href="https://www.wsj.com/livecoverage/stock-market-today-dow-sp500-nasdaq-live-11-18-2024/card/exclusive-trump-to-meet-privately-with-coinbase-ceo-brian-armstrong-DDkgF0xW1BW242rVeuqx?page=1" title="https://www.wsj.com/livecoverage/stock-market-today-dow-sp500-nasdaq-live-11-18-2024/card/exclusive-trump-to-meet-privately-with-coinbase-ceo-brian-armstrong-DDkgF0xW1BW242rVeuqx?page=1">https://www.wsj.com/livecoverage/stock-market-today-dow-sp500-nasdaq-live-11-18-2024/card/exclusive-trump-to-meet-privately-with-coinbase-ceo-brian-armstrong-DDkgF0xW1BW242rVeuqx?page=1</a></p>


COIN

'Coinbase Doled Out More Than $100M To Political Action Committees Before Election; President Trump To Meet Privately With Coinbase CEO Brian Armstrong' - WSJ

Bakkt Holdings Shares Resume Trade

Trump Media & Technology Group shares are trading higher following a report suggesting the company is in talks to acquire a crypto trading venue.

<p><i>– Met primary endpoint with LDL-C mean reduction versus placebo of 36.3% at day 84 and 41.5% at day 365 –</i></p>
<p><i>– Lp(a) mean reduction versus placebo of 45.9% at day 84 and 54.3% at day 365 –</i></p>
<p><i>– Total LDL-P mean reduction versus placebo of 52.5% at day 180, with small LDL-P reduction of 102.4% –</i></p>
<p><i>– Safety results comparable to placebo</i> <i>–</i></p>
<p>NAARDEN, the Netherlands and MIAMI, Nov. 18, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAMS#NASDAQ">NAMS</a>), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease ("CVD") with elevated low-density lipoprotein cholesterol ("LDL-C"), for whom existing therapies are not sufficiently effective or well-tolerated, today announced additional results from the Company's Phase 3 BROOKLYN clinical trial (NCT05425745) evaluating obicetrapib in adult patients with heterozygous familial hypercholesterolemia ("HeFH"), whose LDL-C is not adequately controlled, despite being on maximally tolerated lipid-lowering therapy. The data were presented today in an oral late-breaker presentation at the American Heart Association (AHA) Scientific Sessions.</p>


NAMS

NewAmsterdam Pharma Presents Additional Data From Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib In Patients With Heterozygous Familial Hypercholesterolemia At AHA Scientific Sessions 2024; Met Primary Endpoint With LDL-C Mean Reduction Versus Placebo Of 36.3% At Day 84 And 41.5% At Day 365

Bakkt Holdings Shares Halted On Circuit Breaker To The Upside, Stock Now Up 12.8%

<p><a href="https://www.ft.com/content/d7f921d5-3668-4b6b-a98d-2681ad73610f">https://www.ft.com/content/d7f921d5-3668-4b6b-a98d-2681ad73610f</a><br /><br />Donald Trump's social media company is in advanced talks to buy Bakkt, a cryptocurrency trading venue owned by Intercontinental Exchange, as it pushes to expand beyond online conversation. The US president-elect's Trump Media and Technology Group, in which he has pledged to retain his 53 per cent stake, is closing in on an all-share purchase of Bakkt, said two people with knowledge of the talks. The valuation under discussion was not immediately clear but Bakkt's market capitalisation stood at just over $150mn on Monday. TMTG, which operates Truth Social, has become one of the most actively traded US stocks since Trump's election victory as retail investors try to profit on its often-volatile trading moves. Although it has reported just $2.6mn in revenues this year, TMTG has a $6bn equity valuation, giving its management a valuable currency with which to buy other companies. A successful deal would deepen Trump's move into the cryptocurrency market after he began promoting a new crypto venture set up by longtime business partners, World Liberty Financial, from which he stands to earn significant fees. Crypto markets have also soared following his election victory, with bitcoin up more than 30 per cent on speculation that his administration would enact favourable legislation for the industry. Bakkt, which has struggled for profitability since its launch, was created by ICE, and the owner of the New York Stock Exchange still holds a 55 per cent economic interest in it. Bakkt's first chief executive was Kelly Loeffler, a former head of marketing at ICE and a Republican ex-senator for Georgia during Trump's first presidency. She is co-chair of the committee organising his inauguration in January. She is also married to Jeff Sprecher, ICE's founder, chair and chief executive. ICE and Bakkt declined to comment. TMTG did not immediately respond to a request for comment.</p>


'Donald Trump's Social Media Group In Talks To Buy Crypto Trading Venue; Truth Social Owner Is Close To An All-Share Takeover Of Intercontinental Exchange's Bakkt' - Financial Times

Insider Trades

BorgWarner Form4 Filing Shows VP Stefan Demmerle Sold 21,500 Shares At An Average Price Of $34.79/Share

<p>Financial giants have made a conspicuous bullish move on PDD Holdings. Our analysis of options history for PDD Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDD#NASDAQ">PDD</a>) revealed 87 unusual trades.</p>
<p>Delving into the details, we found 44% of traders were bullish, while 39% showed bearish tendencies. Out of all the trades we spotted, 27 were puts, with a value of $1,964,219, and 60 were calls, valued at $8,300,647.</p>
<h3>What's The Price Target?</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $100.0 to $230.0 for PDD Holdings over the last 3 months. </p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for PDD Holdings's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across PDD Holdings's significant trades, within a strike price range of $100.0 to $230.0, over the past month.</p>
<h3>PDD Holdings Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731960931_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>PDD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$8.45</td>
<td>$7.9</td>
<td>$8.31</td>
<td>$115.00</td>
<td>$2.0M</td>
<td>4.7K</td>
<td>5.0K</td>
</tr>
<tr>
<td>PDD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$8.15</td>
<td>$8.0</td>
<td>$8.0</td>
<td>$115.00</td>
<td>$2.0M</td>
<td>4.7K</td>
<td>2.5K</td>
</tr>
<tr>
<td>PDD</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/13/24</td>
<td>$28.05</td>
<td>$27.75</td>
<td>$27.8</td>
<td>$144.00</td>
<td>$247.4K</td>
<td>0</td>
<td>139</td>
</tr>
<tr>
<td>PDD</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$38.7</td>
<td>$38.45</td>
<td>$38.45</td>
<td>$155.00</td>
<td>$192.2K</td>
<td>1.0K</td>
<td>50</td>
</tr>
<tr>
<td>PDD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$6.3</td>
<td>$6.2</td>
<td>$6.3</td>
<td>$120.00</td>
<td>$184.5K</td>
<td>4.2K</td>
<td>654</td>
</tr>
</tbody>
</table>
</p>
<h3>About PDD Holdings</h3>
<p>PDD Holdings is a multinational commerce group that owns and operates a portfolio of businesses. PDD aims to bring more businesses and people into the digital economy so that local communities and small businesses can benefit from the increased productivity and new opportunities. PDD has built a network of sourcing, logistics, and fulfillment capabilities that support its underlying businesses.</p>
<p>Following our analysis of the options activities associated with PDD Holdings, we pivot to a closer look at the company's own performance.</p>
<h3>Present Market Standing of PDD Holdings</h3>
<ul>
<li>Trading volume stands at 6,199,920, with PDD's price up by 3.47%, positioned at $117.96.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 3 days.</li>
</ul>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.</p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for PDD Holdings with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


Citigourp Global Markets 2% Protected Notes Linked To The Djia

Spotlight on PDD Holdings: Analyzing the Surge in Options Activity

<p>Benzinga's options scanner just detected over 30 options trades for <strong>Freeport-McMoRan</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FCX#NYSE">FCX</a>) summing a total amount of $2,124,128.</p>
<p>At the same time, our algo caught 7 for a total amount of 381,224.</p>
<h3>What's The Price Target?</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $33.0 and $55.0 for Freeport-McMoRan, spanning the last three months.</p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>In today's trading context, the average open interest for options of Freeport-McMoRan stands at 3474.58, with a total volume reaching 28,080.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Freeport-McMoRan, situated within the strike price corridor from $33.0 to $55.0, throughout the last 30 days.</p>
<h3>Freeport-McMoRan 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731960926_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>FCX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$3.95</td>
<td>$3.9</td>
<td>$3.94</td>
<td>$45.00</td>
<td>$338.1K</td>
<td>351</td>
<td>876</td>
</tr>
<tr>
<td>FCX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$1.62</td>
<td>$1.61</td>
<td>$1.62</td>
<td>$46.00</td>
<td>$157.9K</td>
<td>4.0K</td>
<td>2.2K</td>
</tr>
<tr>
<td>FCX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$1.36</td>
<td>$1.31</td>
<td>$1.32</td>
<td>$42.00</td>
<td>$132.0K</td>
<td>8.4K</td>
<td>1.0K</td>
</tr>
<tr>
<td>FCX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$1.8</td>
<td>$1.78</td>
<td>$1.79</td>
<td>$44.00</td>
<td>$118.2K</td>
<td>3.6K</td>
<td>745</td>
</tr>
<tr>
<td>FCX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$3.15</td>
<td>$3.05</td>
<td>$3.15</td>
<td>$45.00</td>
<td>$108.0K</td>
<td>3.7K</td>
<td>577</td>
</tr>
</tbody>
</table>
</p>
<h3>About Freeport-McMoRan</h3>
<p>Freeport-McMoRan Inc is an international mining company. It has organized its mining operations into four primary divisions: North America copper mines, South America mining, Indonesia mining and Molybdenum mines. Its reportable segments include the Morenci, Cerro Verde and Grasberg (Indonesia mining) copper mines, the Rod &amp; Refining operations and Atlantic Copper Smelting and Refining. It derives key revenue from the sale of Copper.</p>
<p>Following our analysis of the options activities associated with Freeport-McMoRan, we pivot to a closer look at the company's own performance.</p>
<h3>Freeport-McMoRan's Current Market Status</h3>
<ul>
<li>With a trading volume of 7,082,008, the price of FCX is up by 1.81%, reaching $43.48.</li>
<li>Current RSI values indicate that the stock is may be approaching oversold.</li>
<li>Next earnings report is scheduled for 65 days from now.</li>
</ul>
<h3>What Analysts Are Saying About Freeport-McMoRan</h3>
<p>A total of 2 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $54.5.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Maintaining their stance, an analyst from Scotiabank continues to hold a Sector Perform rating for Freeport-McMoRan, targeting a price of $52.<br />
&#x2A; An analyst from Raymond James persists with their Outperform rating on Freeport-McMoRan, maintaining a target price of $57. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Freeport-McMoRan, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Spotlight on Freeport-McMoRan: Analyzing the Surge in Options Activity

<p>Deep-pocketed investors have adopted a bearish approach towards Snowflake (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in SNOW usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 86 extraordinary options activities for Snowflake. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 39% leaning bullish and 52% bearish. Among these notable options, 62 are puts, totaling $2,880,105, and 24 are calls, amounting to $1,076,331.</p>
<h3>Predicted Price Range</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $80.0 and $200.0 for Snowflake, spanning the last three months.</p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>In today's trading context, the average open interest for options of Snowflake stands at 930.06, with a total volume reaching 10,549.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Snowflake, situated within the strike price corridor from $80.0 to $200.0, throughout the last 30 days.</p>
<h3>Snowflake Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731960921_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>SNOW</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$43.95</td>
<td>$43.8</td>
<td>$43.95</td>
<td>$170.00</td>
<td>$127.4K</td>
<td>5</td>
<td align="right">29</td>
</tr>
<tr>
<td>SNOW</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$14.05</td>
<td>$14.0</td>
<td>$14.0</td>
<td>$130.00</td>
<td>$106.4K</td>
<td>509</td>
<td align="right">164</td>
</tr>
<tr>
<td>SNOW</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$2.56</td>
<td>$2.5</td>
<td>$2.56</td>
<td>$160.00</td>
<td>$102.4K</td>
<td>3.2K</td>
<td align="right">533</td>
</tr>
<tr>
<td>SNOW</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$19.3</td>
<td>$19.25</td>
<td>$19.25</td>
<td>$140.00</td>
<td>$88.6K</td>
<td>1.8K</td>
<td align="right">98</td>
</tr>
<tr>
<td>SNOW</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/22/24</td>
<td>$4.9</td>
<td>$4.85</td>
<td>$4.9</td>
<td>$122.00</td>
<td>$79.3K</td>
<td>211</td>
<td align="right">197</td>
</tr>
</tbody>
</table>
</p>
<h3>About Snowflake</h3>
<p>Founded in 2012, Snowflake is a data lake, warehousing, and sharing company that came public in 2020. To date, the company has over 3,000 customers, including nearly 30% of the Fortune 500 as its customers. Snowflake's data lake stores unstructured and semistructured data that can then be used in analytics to create insights stored in its data warehouse. Snowflake's data sharing capability allows enterprises to easily buy and ingest data almost instantaneously compared with a traditionally months-long process. Overall, the company is known for the fact that all of its data solutions that can be hosted on various public clouds.</p>
<p>Having examined the options trading patterns of Snowflake, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Where Is Snowflake Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 3,071,577, with SNOW's price up by 0.63%, positioned at $126.75.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 2 days.</li>
</ul>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.</p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Snowflake options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


SNOW

Looking At Snowflake's Recent Unusual Options Activity

Offerings

MDAI

Spectral AI Files For Common Stock Offering Of Up To 1.6M Shares

Analyst Ratings

ACRS

Aclaris Therapeutics Shares Spike Higher; Piper Sandler Upgrades Stock To Overweight With $13 Target Following Biosion Deal; Highlights Pipeline For Atopic Dermatitis And I&I Market, Catalysts Expected In 2025 Trials

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Travere Therapeutics (TVTX – Research Report), Taked...

Analysts Offer Insights on Healthcare Companies: Travere Therapeutics (TVTX), Takeda Pharmaceutical Company (TAK) and Voyager Therapeutics (VYGR)

Scotiabank raised the firm's price target on Travere Therapeutics (TVTX) to $27 from $23 and keeps an Outperform rating on the shares. The company ...

Travere Therapeutics price target raised to $27 from $23 at Scotiabank

In a report released today, Jason Zemansky from Bank of America Securities maintained a Buy rating on Travere Therapeutics (TVTX – Research Report)...

Travere Therapeutics (TVTX) Gets a Buy from Bank of America Securities

Stifel Nicolaus analyst Alex Thompson CFA maintained a Hold rating on Travere Therapeutics (TVTX – Research Report) yesterday and set a price targe...

Stifel Nicolaus Remains a Hold on Travere Therapeutics (TVTX)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Madrigal Pharmaceuticals (MDGL – Research Report), Travere Therap...

Analysts Offer Insights on Healthcare Companies: Madrigal Pharmaceuticals (MDGL), Travere Therapeutics (TVTX) and Regeneron (REGN)

Travere Therapeutics (TVTX) announced that it intends to offer and sell, in an underwritten public offering and subject to market and other conditi...

Travere Therapeutics announces common stock offering, no amount given

Travere Therapeutics announces proposed offering of common stock

The deal priced below last closing price of $17.66. Jefferies and Leerink are acting as joint book running managers for the offering. Published fir...

Travere Therapeutics 7.81M share Spot Secondary priced at $16.00

Travere Therapeutics prices $125M equity offering

The U.K.'s Medicines and Healthcare products Regulatory Agency has approved Travere Therapeutics (TVTX)' medicine sparsentan, or Filspari, to treat...

MHRA approves Travere's sparsentan to treat adults with primary IgAN

MDGL

REGN

VYGR

Health Care

Press Releases

Travere Therapeutics Presents Data Reinforcing Clinical Benefit of FILSPARI® (Sparsentan) in IgAN and Late-Breaking Presentation in FSGS at ASN Kidney Week 2024

Travere Therapeutics Reports Third Quarter 2024 Financial Results

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX

Travere Therapeutics to Present at Upcoming Investor Conferences

Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance

IPOs

Travere Therapeutics Announces Proposed Public Offering of Common Stock

Dividends

Travere Therapeutics Announces Pricing of Public Offering of Common Stock

Travere Therapeutics Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares

Comments

Travere Therapeutics

Travere Therapeutics (TVTX) 옵션

Travere Therapeutics (NASDAQ:TVTX) 주식, 옵션 체인

뉴스

파트너 / 기고자

벤징가 글로벌